IDEXX Laboratories, Inc. $IDXX Stake Reduced by Vontobel Holding Ltd.

Vontobel Holding Ltd. lessened its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 33.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 127,492 shares of the company’s stock after selling 64,416 shares during the quarter. Vontobel Holding Ltd. owned approximately 0.16% of IDEXX Laboratories worth $66,575,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of IDXX. Pension & Wealth Management Advisors Inc. acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth approximately $29,000. Howard Capital Management LLC bought a new stake in IDEXX Laboratories in the 3rd quarter valued at $1,249,000. V Square Quantitative Management LLC raised its stake in IDEXX Laboratories by 4.9% in the 3rd quarter. V Square Quantitative Management LLC now owns 2,171 shares of the company’s stock valued at $1,134,000 after acquiring an additional 102 shares during the period. Assenagon Asset Management S.A. raised its stake in IDEXX Laboratories by 39.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 256,362 shares of the company’s stock valued at $133,870,000 after acquiring an additional 73,129 shares during the period. Finally, Fort Washington Investment Advisors Inc. OH acquired a new stake in IDEXX Laboratories during the 3rd quarter valued at $538,000. Institutional investors own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on IDXX. Wall Street Zen cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. The Goldman Sachs Group began coverage on shares of IDEXX Laboratories in a report on Friday. They issued a “buy” rating and a $740.00 price objective on the stock. JPMorgan Chase & Co. dropped their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating on the stock in a research report on Friday. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Finally, Barclays cut their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $744.09.

Insider Buying and Selling

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the transaction, the director owned 9,568 shares in the company, valued at $5,090,941.44. This trade represents a 18.72% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.79% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock traded up $13.18 on Friday, hitting $560.36. The stock had a trading volume of 708,811 shares, compared to its average volume of 531,547. IDEXX Laboratories, Inc. has a twelve month low of $500.61 and a twelve month high of $769.98. The business’s 50 day moving average is $534.22 and its two-hundred day moving average is $551.84. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. The stock has a market cap of $44.15 billion, a price-to-earnings ratio of 39.41, a price-to-earnings-growth ratio of 2.92 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping the consensus estimate of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period last year, the firm posted $3.50 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Analysts forecast that IDEXX Laboratories, Inc. will post 14.80 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.